Richard Unwin's Contact Details

Richard Unwin's Company Details

Complement Therapeutics

London, England, United Kingdom • 8 Employees
Research

Complement Therapeutics (CTx) is an early stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases as well as developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform. The Company is a spin out from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade whilst the CPM platform employs a unique methodology to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease. Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.